A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients

References

• BrownePChandraratnaDAngoodCAtlas of Multiple Sclerosis 2013: A growing global problem with widespread inequityNeurology201483111022102425200713
   PubMed Web of Science ®Google Scholar
• RansohoffRMHaflerDALucchinettiCFMultiple sclerosis-a quiet revolutionNat Rev Neurol201511313414225686758
   PubMed Web of Science ®Google Scholar
• van den BroekHHDamoiseauxJGde BaetsMHHuppertsRMThe influence of sex hormones on cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis: a reviewMult Scler200511334935915957520
   PubMed Web of Science ®Google Scholar
• Dhib-JalbutSMarksSInterferon-beta mechanisms of action in multiple sclerosisNeurology201074Suppl 1S17S2420038758
   PubMed Web of Science ®Google Scholar
• HutchinsonMNatalizumab: A new treatment for relapsing remitting multiple sclerosisTher Clin Risk Manag20073225926818360634
   PubMedGoogle Scholar
• ZiemssenTSchrempfWGlatiramer acetate: mechanisms of action in multiple sclerosisInt Rev Neurobiol20077953757017531858
   PubMed Web of Science ®Google Scholar
• MillerAEOral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experienceTher Adv Neurol Disord2017101238139629204190
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• MillsEAOgrodnikMAPlaveAMao-DraayerYEmerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple SclerosisFront Neurol20189529410647
   PubMed Web of Science ®Google Scholar
• TorkildsenØMyhrKMBoLDisease-modifying treatments for multiple sclerosis – a review of approved medicationsEur J Neurol201623Suppl 1182726563094
   PubMed Web of Science ®Google Scholar
• GajofattoABenedettiMDTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?World J Clin Cases20153754555526244148
   PubMed Web of Science ®Google Scholar
• LongbrakeEECrossAHSalterAEfficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practiceMult Scler J Exp Transl Clin20162 205521731667786
   Google Scholar
• GuarneraCBramantiPMazzonEComparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosisDrug Des Devel Ther20171121932207
   PubMed Web of Science ®Google Scholar
• EMA European Medicines AgencyInterferon β-1a (Avonex^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdfAccessed September 5, 2018
   Google Scholar
• EMA European Medicines AgencyInterferon β-1a (Rebif^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdfAccessed September 5, 2018
   Google Scholar
• EMA European Medicines AgencyInterferon β-1b (Betaferon^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdfAccessed September 5, 2018
   Google Scholar
• EMA European Medicines AgencyInterferon β-1b (Extavia^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000933/WC500034701.pdfAccessed September 5, 2018
   Google Scholar
• EMA European Medicines AgencyPeginterferon β-1a (Plegridy^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002827/WC500170302.pdfAccessed September 5, 2018
   Google Scholar
• AIFA Italian Drug AgencyGlatiramer acetato (Copaxone^®) Rias-sunto delle caratteristiche del prodotto [Glatiramer Acetate Summary of Product Characteristics] Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002351_035418_RCP.pdf&retry=0&sys=m0b1l3Accessed September 5, 2018
   Google Scholar
• EMA European Medicines AgencyNatalizumab (Tysabris^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdfAccessed September 5, 2018
   Google Scholar
• EMA European Medicines AgencyFingolimod (Gilenya^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdfAccessed September 5, 2018
   Google Scholar
• EMA European Medicines AgencyTeriflunomide (Aubagio^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdfAccessed September 5, 2018
   Google Scholar
• EMA European Medicines AgencyDimethyl fumarate (Tecfidera^®) Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdfAccessed September 5, 2018
   Google Scholar
• ZettlUKHeckerMAktasOWagnerTRommerPSInterferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledgeExpert Rev Clin Immunol201814213715329318902
   PubMed Web of Science ®Google Scholar
• MosesHBrandesDWManaging adverse effects of disease-modifying agents used for treatment of multiple sclerosisCurr Med Res Opin20082492679269018694542
   PubMed Web of Science ®Google Scholar
• Biogen Medical Information [webpage on the Internet]PML Incidence in Patients Receiving Tysabri^® Available from: https://medinfo.biogen.com/Accessed September 5, 2018
   Google Scholar
• O’ConnorPGoodmanAKapposLLong-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS StudyNeurology2014831788624898925
   PubMed Web of Science ®Google Scholar
• GiacoppoSRuscicaMGrimaldiLMBramantiPMazzonEThe Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis TherapyMed Sci Monit2017234230424028864818
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• CalabresiPARadueEWGoodinDSafety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Neurol201413654555624685276
   PubMed Web of Science ®Google Scholar
• MahajanKRKoJSTetzlaffMTHudgensCWBillingsSDCohenJAMerkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case reportMult Scler Relat Disord201717121429055440
   PubMed Web of Science ®Google Scholar
• WalkerSBrewBKaposi sarcoma in a fingolimod-treated patient with multiple sclerosisJ Clin Neurosci20163121721827168454
   PubMed Web of Science ®Google Scholar
• ConzettKBKolmIJelcicIMelanoma occurring during treatment with fingolimod for multiple sclerosis: a case reportArch Dermatol2011147899199221844470
   PubMedGoogle Scholar
• WhiteCAlshakerHCooperCWinklerMPchejetskiDThe emerging role of FTY720 (Fingolimod) in cancer treatmentOncotarget2016717231062312727036015
   PubMed Web of Science ®Google Scholar
• ZhangNQiYWadhamCFTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagyAutophagy2010681157116720935520
   PubMed Web of Science ®Google Scholar
• LeeJWRyuJYYoonGSphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancerInt J Cancer2015137122122925429856
   PubMed Web of Science ®Google Scholar
• MarrieRAHorwitzRIEmerging effects of comorbidities on multiple sclerosisLancet Neurol20109882082820650403
   PubMed Web of Science ®Google Scholar
• FloresJRitoYTorresGJungHTreviño-FrenkICoronaTHypothyroidism in multiple sclerosis patient during fingolimod treatmentJ Neurol Sci20153481–227227325491264
   PubMed Web of Science ®Google Scholar
• LoreficeLFenuGGereviniSPML in a person with multiple sclerosis: Is teriflunomide the felon?Neurology2018902838529212829
   PubMed Web of Science ®Google Scholar
• BergerJRClassifying PML risk with disease modifying therapiesMult Scler Relat Disord201712596328283109
   PubMed Web of Science ®Google Scholar
• RahmlowMShusterEADominikJLeflunomide-associated progressive multifocal leukoencephalopathyArch Neurol200865111538153919001176
   PubMed Web of Science ®Google Scholar
• WarnatzKPeterHHSchumacherMInfectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literatureAnn Rheum Dis2003621505712480669
   PubMed Web of Science ®Google Scholar
• DahdalehDAltmannDMMalikONicholasRSBreathlessnessNRSBreathlessness, night sweats, and weight loss on natalizumabLancet2012380984372672722920745
   PubMed Web of Science ®Google Scholar
• de MassonAMaillartEVezirisNMeyssonnierVPapeixCCaumesECavitary pulmonary disease in a patient treated with natalizumabPresse Med20144391009101224742610
   PubMed Web of Science ®Google Scholar
• HradilekPZemanDTudikIZapletalovaOUlmannVAsymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosisMult Scler201420563964023959714
   PubMed Web of Science ®Google Scholar
• LoreficeLFenuGCabrasFAn unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitisMult Scler Relat Disord20167656727237760
   PubMed Web of Science ®Google Scholar
• KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837296481463147218970976
   PubMed Web of Science ®Google Scholar
• BernardiniLRZeccaCClericiVTGobbiCMantegazzaRRossiSSevere articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosisJ Neurol Sci201636913914027653880
   PubMed Web of Science ®Google Scholar